Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 2, 2009

Amylin to Receive $75M in Obesity Alliance with Takeda

  • Amylin Pharmaceuticals and Takeda Pharmaceutical are joining forces to develop and commercialize therapies for obesity and related indications. Takeda will pay Amylin $75 million up front for a license to its Phase II program with pramlintide/metreleptin and davalintide.

    Amylin stands to earn $1 billion in development, commercialization, and sales-based milestones. The agreement also includes additional compounds from both companies' obesity research programs.

    Amylin is responsible for developing each potential molecule through Phase II in the U.S. Takeda will lead development beyond Phase II in the U.S. and all development activities outside the U.S. In most instances, Amylin will be responsible for 20% of development costs associated with obtaining approval for products in the U.S. Takeda will be responsible for 100% of development costs associated with obtaining approval for products outside the U.S.

    Takeda will lead product commercialization, both in the U.S. and outside the U.S., and will be responsible for 100% of commercialization costs. Amylin will receive tiered, double-digit royalty payments based on global product sales. Amylin also has the option to co-commercialize the first two approved products in the U.S. and any follow-on products containing the identical active ingredients.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »